Sign in
Not yet recruitingPhase 2/3

Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

Key facts

Who runs it
GC Biopharma Corp
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
1,806 people, planned
Started
Oct 2026
Expected to end
Aug 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • vaccination of GC3114B
  • Vaccination of Efluelda
Record updated
20 October 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adults aged 65 years or older at the time of IP vaccination
  • Subjects who have voluntarily decided to participate in the study after receiving and understanding a detailed explanation of the study and provided written informed consent to comply with the precautions

Who cannot take part

  • History of severe hypersensitivity reactions after previous influenza vaccination or to eggs or any component of the vaccine (see Section 6.1) (e.g., anaphylaxis)
  • Record of an influenza vaccination within 24 weeks prior to IP vaccination
  • Known or suspected history of impaired immune function, including congenital or acquired immunodeficiency disorders
  • History or family history of Guillain-Barre syndrome

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older. The study will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.

Read full original descriptionShow less

After providing written informed consent, participants will undergo screening to determine whether they are eligible. Eligible participants will be randomly assigned to a study group and receive a single dose of the investigational product on Day 0.

Participants will record solicited adverse events in a subject diary from Day 0 through Day 7. The study site will contact participants by telephone on Day 7 to check on adverse events, concomitant medications, and diary completion. On Day 28, participants will visit the study site for safety follow-up and blood sampling. Participants will be monitored for serious adverse events for 6 months.

The 2 groups in the trial

  • GC3114BTreatment being tested

    inactivated, split influenza vaccine

    Treatment: vaccination of GC3114B

  • EflueldaExisting treatment, for comparison

    Inactivated split influenza vaccine

    Treatment: Vaccination of Efluelda

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Record updated
20 October 2026